Houston cancer-fighting organization launches center to support early clinical trials
new to hou
Cancer treatment in Houston just became even more promising — and forward-thinking.
Phase 1 clinical trials are necessary to prove the efficacy in humans of treatments that have appeared promising in lab trials. In the name of cancer-fighting innovation, Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center has launched the Albert and Margaret Alkek Foundation Center for Experimental Therapeutics.
The new center is specifically designed to allow patients to be on the cutting edge of testing brand-new therapies that could save their lives.
“Clinical trials are critical for advancing the field of oncology and improving outcomes for cancer patients. Phase 1 trials are the first step in bringing innovative therapies to the clinic,” says Dr. Benjamin Musher, Barry S. Smith endowed professor at Baylor and medical director of medical oncology at the Duncan Cancer Center McNair Campus, in a news release. “Our new program will build on the success of previous phase 1 trials at Baylor and provide robust infrastructure to offer more clinical trial opportunities to our patients.”
The Alkek Foundation Center’s team practices across all specialty areas, allowing a broad swath of the Cancer Center’s patients to take part and to continue to receive care from the sub-specialty doctors they know and trust. And even if they aren’t already being treated at Baylor, physicians from outside Baylor can refer patients to the program through a smooth process.
“We are excited to offer novel research treatment options to our cancer patients at our state-of-the-art unit,” says Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center and senior associate dean of cancer programs at Baylor. “This program will increase the scope of our research while giving the cancer patients in our community access to first in human and cutting-edge clinical trials.”
Patients will be treated at Duncan Cancer Center’s clinical home, Baylor St. Luke’s Medical Center’s O’Quinn Medical Tower at the McNair Campus. As interim dean of research and dean of the Graduate School of Biomedical Sciences at Baylor, Carolyn Smith says, with the new center, Baylor is “advancing medicine by taking innovations made in the lab and moving them to the bedside.”
The debut trial to take place at the center enrolled its first patient this month. It will test a novel therapy that targets a mutation commonly found in pancreatic and colorectal cancers.
“Phase 1 oncology clinical trials provide patients early access to cutting-edge therapeutics and immunotherapies that are not widely available. Patients in these trials are often selected because their tumors have a molecular feature that is targeted by these therapies,” says Dr. S. Gail Eckhardt, who is Baylor’s Albert and Margaret Alkek endowed chair and serves as associate dean for experimental therapeutics at Baylor and associate director of translational research at the Duncan Cancer Center.
- Houston health care institutions receive $22M to attract top recruits ›
- Baylor scientist wins award for young chemists, scores $3M for groundbreaking cancer tech ›
- Baylor Medicine opens innovatively inclusive dermatology center in Houston ›
- Houston health care institution secures $100M for expansion, shares renderings ›
- Houston organizations snag chunk of recently announced $49M cancer research grant funding ›
The Baylor campus is next to Texas Medical Center’s Helix Park, a 37-acre project. Rendering courtesy of BCM
The Cullen Foundation donated $30 million to the project. Rendering courtesy of BCM
